Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2025—A study analyzed data from 6,068 individuals who received a commercial blood-based CRC screening test between May 2022 and September 2024. The study found that 49% of individuals with an abnormal result received a follow-up colonoscopy within six months, with a mean time of 66.4 days.
November 2025—A HER2-low–focused IHC scoring system was validated by nine breast pathologists using digitized images of HER2 IHC slides. The system demonstrated high performance metrics, including accuracy, sensitivity, and specificity, across two data sets, validating its effectiveness.
November 2025—A study of four laboratories’ experiences with subclassifying variants of uncertain significance (VUS) found that variants were more likely to be reclassified as benign than pathogenic. The VUS-high subclass had the highest percentage of reclassifications, but represented a smaller proportion of total VUS classifications.
November 2025
Q. Clinicians at my hospital doubt my prolactin results. They report patients with prominent pituitary adenomas who have normal prolactin results. There are other patients who have hyperprolactinemia but no adenoma or galactorrhea. In those patients, the prolactin concentrations remain elevated even after therapy. Can you clarify? Read answer.
Q. Is it necessary for a lab to report a corrected sodium level when the glucose level is really high? Studies show pseudohyponatremia can occur due to hyperglycemia. How common is this, and how do we decide which correction factor to use? Is it possible that this is easily overlooked by providers due to comorbidities in patients? Some references say there is a need to correct glucose for each 100 mg/dL increase above 400 mg/dL. Read answer.
November 2025—UpToDate, a widely used clinical decision support tool, is facing competition from OpenEvidence, an AI-powered tool that provides more accurate and context-specific answers to complex clinical cases. While UpToDate is adding its own AI capabilities, the optimal source of truth for AI-driven clinical decision support remains uncertain.
November 2025—The FDA cleared Roche’s Elecsys pTau181 test, a blood-based biomarker for Alzheimer’s disease assessment in patients 55 and older. The CAP requested an exception for physician J-1 visa holders, concerned the proposed four-year visa limit could hinder international medical graduates pursuing pathology careers. The Association for Molecular Pathology and CAP published a consensus recommendation for a simplified next-generation sequencing molecular biomarker report template.
October 2025—For my inaugural column in CAP TODAY, I’d like to begin by saying thank you. Thank you, CAP members, for the honor of allowing me to serve as your president. Thanks to my mentors, peers, and colleagues for helping me along this path. And my deepest gratitude to my wife, Jenny, and my daughter, Jasmine, for the extraordinary journey that began in China and led to my own American dream in the U.S. and to Louisiana, where I practice.
October 2025—Whole genome sequencing is being evaluated in newborn screening to increase the diagnosis and treatment of rare clinical conditions. Such screening raises ethical questions about which results to report and the impact of those results on parents and their children. It is important to focus on societal norms when designing whole genome sequencing–newborn screening (WGS-NBS) to make sure people accept the testing and minimize patient harm. Although parents value the fact that WGS-NBS can lead to early diagnosis and treatment of various conditions, they recognize that results may cause psychological distress, eliminate children’s autonomy, raise data-storage and privacy concerns, and lead to uncertainty regarding adult-onset medical conditions. The public, in general, supports WGS-NBS for clinically actionable childhood-onset conditions, with the caveats that health professionals are trained to interpret such results and genetic counseling is available.
October 2025—Crystal-storing histiocytosis is a rare disorder in which crystals accumulate in the cytoplasm of histiocytes. It is usually associated with a lymphoplasmacytic neoplasm. Cutaneous crystal-storing histiocytosis (CSH) is extraordinarily rare and limited to case reports in the literature. The authors reported on two cases of CSH with cutaneous involvement. Case one was a 65-year-old male with a four-month history of a pruritic eruption that started as a solitary pink to skin-colored indurated plaque on the anterior neck before progressing to involve the whole neck, chest wall, and face.
October 2025—GATA2 deficiency is a rare inherited condition that disrupts the normal development of blood and immune cells. People born with this genetic disorder may experience low blood counts, frequent infections, or such problems as lymphedema and hearing loss. The most serious long-term risk is development of myelodysplastic syndrome (MDS), a bone marrow disorder that can progress to leukemia. The authors conducted a large study in which they followed 218 people with confirmed GATA2 mutations to understand when and how MDS develops. In this cohort, symptoms of GATA2 deficiency were present in 205 of the participants, of whom 187 (91.2 percent) had MDS.
